Organization (Academic)
University of Montana
ClinicalTrials.gov lists University of Montana as lead sponsor of 28 trials. It has 8 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 5 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo University of Montana, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers University of Montana: 28 lead-sponsored trials and 1 legal-entity registration. The parent company on record for University of Montana is Montana University System, which does not have its own page on this site.
Disease areas (34)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Chronic Cough | 5 |
| Cough | 5 |
| Substance-Related Disorders | 3 |
| Dizziness | 2 |
| Coronary Disease | 2 |
Showing 5 of 34 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 3 |
| 2019 | 1 |
| 2018 | 2 |
| 2016 | 1 |
| 2015 | 2 |
Showing 10 of 15 years.
Prediction, not a registry value: median of 35 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 15 months across 15 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (8)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Behavioral Treatment | Chronic Cough | Early 1 | 1 |
| Behavioral Treatment | Cough | Early 1 | 1 |
| Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer | Cough | Early 1 | 1 |
| Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer | Cough | Early 1 | 1 |
| Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer | Chronic Cough | Early 1 | 1 |
Showing 5 of 8 active programs.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 20% hit target (n=10) | 33% on time (n=9) |
Biomarker capability evidence (11)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| KITLG | Trial collaborator | Named in trial inclusion criteria |
| PLA1A | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial exclusion criteria |
| SERPINF2 | Trial collaborator | Named in trial exclusion criteria |
| ACE | Trial sponsor | Mentioned in trial text |
Showing 5 of 11 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Counted at group level under Montana University System: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.